https://scholars.lib.ntu.edu.tw/handle/123456789/458876
標題: | Impact of high-volume disease in Asian population with newly diagnosed metastatic prostate cancer | 作者: | Cheng Y.-T. JIAN-HUA HONG Lu Y.-C. YEONG-SHIAU PU CHAO-YUAN HUANG KUO-HOW HUANG Liu S. CHUNG-HSIN CHEN |
公開日期: | 2018 | 卷: | 29 | 期: | 3 | 起(迄)頁: | 136-144 | 來源出版物: | Urological Science | 摘要: | Purpose: The purpose of this study is to investigate the clinical oncological outcomes and prognostic factors of high-volume disease (HVD) in the Asian population with metastatic hormone-sensitive prostate cancer. Methods: We retrospectively analyzed 503 patients with newly diagnosed metastatic prostate cancer. Patients were classified as HVD if visceral metastases were present and/or ?4 bone lesions with ?1 lesion beyond the vertebral bodies and pelvis. Overall survival (OS) and cancer-specific survival were investigated based on the disease burden. The Cox proportional hazards regression model was used to evaluate the prognostic factors. Results: About 50.7% patients were classified as low-volume disease (LVD) and 49.3% were HVD at diagnosis. The medians of OS and cancer-specific survival were 64 and 116 months, respectively, for patients with LVD and 26 and 46 months, respectively, for men with HVD (both P < 0.001). Among patients with HVD, 76.6% had both high-volume bone disease (HBD) (?4 bone metastases) and appendicular bone involvement. There was no significant difference in both OS and cancer-specific survival between patients with visceral metastases and those with HBD combined with appendicular bone involvement. In the multivariable analysis, presence of Gleason score ?8, HBD, or HVD may predict poorer OS and cancer-specific survival outcomes (all P < 0.05). Conclusions: Asian patients with high-volume metastatic prostate cancer had a larger proportion of HBD with appendicular bone involvement, who had a comparably poor prognosis to those with visceral metastases. Patients with HBD or HVD had reduced survival outcomes. ? 2018 Medknow Publications. All rights reserved. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/458876 | DOI: | 10.4103/UROS.UROS_11_18 | SDG/關鍵字: | abiraterone acetate; alkaline phosphatase; cisplatin; docetaxel; enzalutamide; fluorouracil; folinic acid; hemoglobin; lactate dehydrogenase; paclitaxel; prostate specific antigen; age; aged; alkaline phosphatase blood level; androgen deprivation therapy; Article; Asian; bone metastasis; bone scintiscanning; cancer chemotherapy; cancer grading; cancer growth; cancer localization; cancer mortality; cancer prognosis; cancer specific survival; cancer staging; cohort analysis; computer assisted tomography; digital rectal examination; disease burden; distant metastasis; follow up; Gleason score; hemoglobin blood level; human; lactate dehydrogenase blood level; lymph node metastasis; major clinical study; male; nuclear magnetic resonance imaging; overall survival; population density; priority journal; prostate adenocarcinoma; retrospective study; sex ratio; tumor volume; visceral metastasis |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。